CMO taps Capsugel for early-phase supply edge

UK contract manufacturer Molecular Profiles is adding an Xcelodose 1205 powder micro-doser for capsule and vial filling. The purchase furthers the company's goal of expanding into early-phase drug trial supply production.

The Xcelodose unit, made by Pfizer's Capsugel group, provides for dosing of drug materials in quantities as small as 100 micrograms. Such precision is especially beneficial in early-phase trial materials because it eliminates the need for formulation development and stability studies, the company says.

Separately, Capsugel has garnered rights to the FlexTab dosage-form technology. The oral-delivery formulation platform, based on injection-molding technology, follows eight years of collaboration with drug giant GSK.

- see the Molecular Profiles release
- here's the FlexTab announcement

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.